ovarian cancer
Showing NaN - NaN of 220
Solid Tumor, Adult, Colorectal Cancer, NSCLC Trial in United States (A2B694, xT CDx with HLA-LOH Assay)
Not yet recruiting
- Solid Tumor, Adult
- +19 more
- A2B694
- xT CDx with HLA-LOH Assay
-
Duarte, California
- +9 more
Sep 22, 2023
Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)
Not yet recruiting
- Ovarian Cancer
- Malignant Neoplasm of Uterus
-
New York, New YorkIcahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified
Recruiting
- Endometrial Cancer
- +8 more
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
-
Orlando, Florida
- +21 more
Feb 2, 2023
Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Worldwide (biological, drug, other)
Recruiting
- Ovarian Cancer
- +2 more
- Pembrolizumab
- +4 more
-
Phoenix, Arizona
- +178 more
Jan 25, 2023
Ovarian Cancer, NSCLC, ESCC Trial in United States (ASP0739, Pembrolizumab)
Active, not recruiting
- Ovarian Cancer
- +3 more
-
Duarte, California
- +6 more
Jan 21, 2023
Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)
Recruiting
- Minimal Residual Disease
- +11 more
- ELI-002 2P
-
Duarte, California
- +10 more
Jan 18, 2023
Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)
Recruiting
- Advanced Malignancies
- +4 more
- Avelumab
- +7 more
-
Fayetteville, Arkansas
- +61 more
Jan 10, 2023
NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)
Recruiting
- Non-small Cell Lung Cancer
- +11 more
-
Birmingham, Alabama
- +32 more
Jan 4, 2023
Ovarian Cancer, Cervical Cancer, Endometrial Cancer Trial in Worldwide (Enapotamab vedotin (HuMax-AXL-ADC))
Completed
- Ovarian Cancer
- +7 more
- Enapotamab vedotin (HuMax-AXL-ADC)
-
Phoenix, Arizona
- +40 more
Dec 12, 2022
Ovarian Cancer Trial in Worldwide (VS-6766, VS-6766 and Defactinib)
Recruiting
- Low Grade Ovarian Serous Adenocarcinoma
- Ovarian Cancer
- avutometinib (VS-6766)
- avutometinib (VS-6766) and Defactinib
-
Scottsdale, Arizona
- +46 more
Dec 29, 2022
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics Trial in Worldwide (AZD5363)
Active, not recruiting
- Advanced Solid Malignancy
- +13 more
-
Los Angeles, California
- +33 more
Dec 22, 2022
Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)
Terminated
- Platinum Sensitive Ovarian Cancer
- Ovarian Cancer
- FRĪ± peptide plus Adjuvant (GM-CSF)
- Adjuvant (GM-CSF) Alone
-
Birmingham, Alabama
- +17 more
Nov 21, 2022
Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or
Active, not recruiting
- Melanoma
- +8 more
- Pegilodecakin
- +9 more
-
Los Angeles, California
- +9 more
Nov 15, 2022
Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer Trial in Duarte, Louisville, New York (PF-07263689, Sasanlimab)
Active, not recruiting
- Renal Cell Cancer
- +9 more
- PF-07263689
- Sasanlimab
-
Duarte, California
- +5 more
Nov 8, 2022
Melanoma, Ovarian Cancer, Sarcoma Trial in Italy, Portugal, United States (IGIMRT using a single dose of 24 Gy, IGIMRT 27 Gy in
Active, not recruiting
- Melanoma
- +6 more
- IGIMRT using a single dose of 24 Gy
- IGIMRT 27 Gy in 3 fractions
-
San Francisco, California
- +3 more
Nov 1, 2022
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York
Recruiting
- Advanced Solid Tumor
- +13 more
- [225Ac]-FPI-1966
- +2 more
-
Duarte, California
- +3 more
Oct 25, 2022
Ovarian Cancer Trial in New York (Monoclonal antibody hu3S193)
Terminated
- Ovarian Cancer
- Monoclonal antibody hu3S193
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Oct 3, 2022
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer Trial in New York (NY-ESO-1 peptide vaccine)
Completed
- Fallopian Tube Cancer
- +2 more
- NY-ESO-1 peptide vaccine
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Oct 3, 2022